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Summary: The performance characteristics of an immunoradiometric assay for bone alkaline phosphatase mass
concentration in human sera are reported.
Within-run imprecision (n = 20) was 12.1% (x = 7.8 μ§/\) and 3.6% (x = 22.8 Mg/1), between-day imprecision
(n = 8) was 10.1% (X = 20.3 μ£/1) and 2.8% (x = 84.3 μ§/1). There was a linear relationship between the concen-
trations of the Standards employed and the counts per minute up to 120 μ^Ι. The detection limit was 0.3
In 102 apparently healthy persons (51 males and 51 females; r nge of age: 18-56 years) the following reference
intervals were established: 3.8—21.3 μg/l (males) and 3.4—15.0 μg/l (females).
We compared the values obtained using the immunoassay with those obtained by precipitating of bone alkaline
phosphatase with wheat-germ lectin (alkaline phosphatase activity concentration was determined at + 25 °C by the
optimized Standard method according to the Recommendations of the German Society for Clinical Chemistry). For
the reference individuals the relationship between the results pf the two methods is given by the following regression
equation: Bone alkaline phosphatase activity concentration [U/l] = 14.81 + 3.28 X bone alkaline phosphatase mass
concentration [jigft] (r = + 0.783). In 89 sera from 32 patients before and after renal transplantation (r nge of bone
alkaline phosphatase mass concentration: 2—39 μg/l) comparison between the two methods yielded a linear corre-
lation coefficient of r = + 0.886.
Of 20 sera taken from patients suffering from various hepatobiliary diseases (r nge of total alkaline phosphatase
activity concentration: 217—3270 U/l) 18 (90%) showed a bone alkaline phosphatase mass concentration above the
upper reference limit (r nge of bone alkaline phosphatase mass concentration: 16—206 μg/l). This is probably due
to a cross-reactivity of the antibodies employed for the immunoassay of bone alkaline phosphatase with liver
alkaline phosphatase in plasma. It is concluded that an increased release of liver alkaline phosphatase into serum
leads to falsely high values for bone alkaline phosphatase mass concentration, severely limiting the diagnostic
validity of the test in such cases.
Introduction Several methods have been recommended for differen-
tiating between liver and bone alkaline phosphatases,
Human alkaline phosphatases (orthophosphoric mono-
 based on the foilowing principles:
ester phosphohydrolase [alkaline Optimum], EC 3.1.3.1)
are glycoproteins which can bedivided into at least four (a) Separation of bone and liver isoforms by electro-
isoenzyme groups: intestinal, placental, placental-like pnoresis (2)
and hepatic/renal/skeletal. The alkaline phosphatases of (b) Precipitation of bone alkaline phosphatase with
bone and liver are coded by a sragle gene but differ in wheat-germ lectin, which leaves non-bone alkaline
their degree of glycosylation (for review see 1. c. (1)). phosphatases in the supernate (3).
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Here we report on the evaluation of an immunoradio-
metric method for determination of bone alkaline phos-
phatase mass concentration in human sera. The method
employs two monoclonal antibodies, which react with
different epitopes of the bone alkaline phosphatase mol-
ecule.
Materials and Methods
Reference individuals and patients
Sera were obtained frorn
(a) 102 apparently healthy persons (51 males and 51 females, re-
spectively), age r nge 20—55 years (median: 30 years) for
males, and 18-56 years (median: 29 years) for females.
(b) 32 patients receiving renal transplants (10 sera before and 79
sera l week to 6 months after transplantation).
(c) 20 patients with various hepatobiliary diseases.
All specimens were taken between 8 and 9 a. m. Sera were separ-
ated frorn the blood clot within 4 h after specimen collection and
stored at -20 °C for a period of up to 2 months.
Determination of bone alkaline phosphatase mass
concentration in serum
Bone alkaline phosphatase mass concentration was determined by
an immunoradiometric assay (Tandem®-R Ostase™; Hybritech
Inc., San Diego, CA [U. S. A.]; No. 3040 BE; lot No. 35 077 08G):
100 μΐ of serum were mixed with a plastic sphere coated with
antibody and 100 μΐ of 125I-labelled second antibody. The reaction
mixture was incubated for 17-21 h at temperatures not above
+ 8 °C. After three washing Steps, radioactivity bound to the
spheres was measured with a scintillation counter. The Standards
used had the following concentrations: 0, 15, 30, 45, 60 and 120
^ig/l, respectively. A calibration curve was constructed by linear
Interpolation between the measuring points. There was a linear re-
lationship between the concentrations of the Standards employed
and the counts per minute up to 120 μg/l.
Determination of bone alkaline phosphatase activity
concentration in serum
Bone alkaline phosphatase activity concentration was determined
according to Rosalki & Ying Foo (3) by employing Iso-ALP (Boeh-
ringer Mannheim GmbH, Mannheim, Germany; No. 1065769; lot
No. 641713): 100 μΐ of serum were mixed with 100 μΐ of a solution
containing wheat-germ lectin (> 2 g/l) for precipitatioh of bone
alkaline phosphatase and Triton X-100 (20 g/l) to prevent copre-
cipitation of biliary alkaline phosphatase. After incubation for 30
min at room temperature the mixture was centrifuged at 2500 g for
10 min. The activity of total alkaline phosphatase in serum and of
alkaline phosphatase in the supernate was measured at + 25 °C by
the optimized Standard method according to the Recommendations
of the German Society for Clinical Chemistry (4) using the fully
mechanized analyser Hitachi/BM 704 (Boehririger Mannheim
GmbH, Mannheim, Gerraany). Bone alkaline phosphatase activity
concentration was caiculated with the aid of the following equation
which takes into account dilution of serum by the precipitating
reagent s well s an average of 10% residual activity of bone
alkaline phosphatase in the supernate and an average of 5% of non-
bone alkaline phosphatase in the precipitate (5):
Bone alkaline phosphatase activity concentration (in serum) [U/l]
= 1.118 X total alkaline phosphatase activity concentration (in
serum) [U/l] — 2.35 X alkaline phosphatase activity concentration
(in the supernate) [U/l].
Determination of Ζ,-γ-glutamyl transferase in serum
Ζ,-γ-glutamyl transferase (EC 2.3.2.2) activity concentration was
determined according to Szasz (6) using the fully mechanized ana-
lyser Hitachi/BM 737 (Boehringer Mannheim GrnbH, Mannheim,
Germany) (reference r nge: 6-28 U/l [males] arid 4-18 U/l [fe-
males]).
Statistical analysis
The statistical methods employed include the U-test according to
Wilcoxon, Mann & Whitney (two-tailed), linear correlatipn coef-
ficients and linear regression equations (7).
Results
Imprecision
Two pooled human sera were analysed 20 times for de-
termination of bone alkaline phosphatase mass concen-
tration and activity concentration, respeetively, in order
to assess within-run imprecision (tab. 1). The results of
between-day imprecision are shown in table 2.
Assay limit of detection
Twenty replicate analyses of the zero Standard were
made within a single run, and the assay limit of detec-
tion, defined s the concentration cprresponding to the
95% confidence interval of counts, was found to be 0.3
Linearity and dilution
Linearity of dilution was investigated using 2 human
serum samples containing 22.6 and 81.4 μg/l bone alka*
Tab. l Comparison of the immunoradiometric determination of
bone alkaline phosphatase mass concentration and the determi-
nation of bone alkaline phosphatase activity concentration by pre-
cipitation with wheatrgerm lectin, with respect to within-run impre-
cision (n = 20).
Sample
Pooled serum I
Pooled serum I
Pooled serum II
Pooled serum II
Determination of
mass concentration
activity concentration
mass concentration
activity concentration
Mean
7.8 μ '^
50.7 U/l
22.8 μβ/1
11 0.5 U/l·
Standard deviation
0.94 μg/l
1.1 U/l
0.81 μg/l
3.9 U/l
Coefficient of Variation
12.1%
2.2%
3.6%
3.5%
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Tab. 2 Between-day imprecision of the immunoradiometric deterraination of bone alkaline phospha-
tase mass concentration (n = 8)
Quality control material
Low control3
High controla
Mean
20.3
84.3
Standard
deviation
2,05
2.36
Coefficient
of Variation
10.1
2.8
Confidence interval
quoted by the manufacturer
[W/u
17.2- 25.0
70 -116
a
 Hybritech Inc., San Diego, CA [U. S. A.] (component of Tandem®-R Ostase™; No. 3040 BE;
lotNo. 3507708G)
line phosphatase. Varying dilutions (9 + l, 8 + 2, ...,
l + 9) were made, employing the zero Standard s dilu-
ent. Data are shown in figure 1. The corresponding re-
gression line did not significantly differ from the bisec-
tor of the diagram. After correcting the measured con-
centrations for the dilution factor and expressing them
s a percentage of the concentration measured in the
undiluted sample, the recovery was found to r nge from
88% to 113% (mean: 103%).
Method comparison
Comparisons between bone alkaline phosphatase mass
concentration and activity concentration in reference in-
dividuals, s well s in patients receiving renal trans-
plants, are given in figures 2 and 3. From the linear
0 10 20 30 40 50 60 70 80 90
Bone alkaline phosphatase
mass concentration expected [jjg/l]
Fig. l Linearity of dilution.
Two human sera (designated by βςμαΓββ and circles, respectively)
were diluted s described under Results. The line corresponds to
the bisector of the diagram.
regression equations obtained (see legends to figs. 2 and
3) it can be calculated that a bone alkaline phosphatase
activity concentration of 100 U/l corresponds to a bone
alkaline phosphatase mass concentration of 26 μg/l.
Reference interval
In apparently healthy persons bone alkaline phosphatase
mass concentration was higher in males than in females
(p < 0.0001). The reference intervals (2.5th-97.5th
percentile) are 3.8-21.3 μg/l (median: 10.2 μg/l)
(males) and 3.4-15.0 μg/l (median: 6.9 μg/l) (females)
(fig.4).
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Fig. 2 Comparison of the alkaline phosphatase mass concen-
tration ( s determined by an immunoradiometric assay) and the
bone alkaline phosphatase activity concentration ( s determined by
precipitation with wheat-germ lectin) in 102 apparently healthy
persons.
The relationship between activity concentration and mass concen-
tration is given by the following regression equation: Bone alkaline
phosphatase activity concentration [U/l] = 14.81 -h 3.28 X bone
alkaline phosphatase mass concentration [ng/l] (r = + 0.783).
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For bone alkaline phosphatase activity concentration the
following reference intervals (2.5th-97.5th percentile)
were determined: 29-91 U/l (median: 52 U/l) (males)
and 23-73 U/l (median: 35 U/l) (females).
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Fig. 3 Comparison of the bone alkaline phosphatase mass con-
centration (äs determined by an immunoradiometric assay) and the
bone alkaline phosphatase activity concentration (äs determined by
precipitation with wheat-germ lectin) in 89 sera from 32 patients
receiving renal transplants.
The relationship between activity concentration and mass concen-
tration is given by the following linear regression equation: Bone
alkaline phosphatase activity concentration [U/l] = 6.77 + 3.56 X
bone alkaline phosphatase mass concentration |>g/l] (r =
+ 0.886).
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Fig. 4 Distribution of bone alkaline phosphatase mass concen-
tration in apparently healthy persons.
Black bars: males (n = 51); white bars: females (n ?= 51).
Interference by non-bone alkaline
phosphatase
In 20 sera ftom patients with hqpatobiliary diseases the
ränge of total alkaline phosphatase activity concen-
tration was 217-3270 U/l (median: 376 U/l), and of L-
-glutamyl transferase activity .concentration 25-640
U/l (median: 120 U/l).
The ränge of bone alkaline phosphatase mass concen-
tration in these patients was 16—206 pg/l (median: 27
g/l). Out of 20 sera, 18 (90%) showed a bone alkaline
phosphatäse mass concentration aböve the upper refer-
ence limit (21.3 §/1 [males] and 15.0 g/l [females],
respectively). The relationship between total alkaline
phosphatase activity concentration and bone alkalirjie
phosphatase mass concentration was characterized by a
linear correlation cqefficient of r = + 0.963
(p < 0.001) (fig. 5).
The ränge of bone alkaline phosphatase activity concen-
tration was 17-166 U/l (median: 65 U/l). Out of 20
sera, 9 (45%) were characterized by a bone alkaline
phosphatase activity concentration above the reference
limit (91 U/l [males] and 73 U/l [females], respectively).
There was no correlation between total alkaline phos-
phatase activity concentration and bone alkaline phos-
phatase activity concentration (p > 0.1).
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Fig. 5 Relationship between bone alkaline phosphatase mass <con-
centration and total alkaline phosphatase actiyity concentration in
20 patients with hepatobiliary diseases.
The relationship between the results of the two methods is given
by the following linear regression equation: Bone alkaline phos-
phatase raass concentration [|ig/l] = 6,779 + 0.059 X total alka-
line phosphatase activity concentration [U/l] (r = + 0.963, p <
0.001).
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Discussion
The immunoradiometric determination of bone alkaline
phosphatase is characterized by a linear relationship be-
tween the mass concentration of bone alkaline phospha-
tase and the measuring signal up to 120 §/1.
A drawback of the immunoradiometric assay is its high
within-run and between-day imprecision for values
within the normal ränge.
The upper reference limits of bone alkaline phosphatase
activity concentration established by us correspond to
those reported earlier (5). There is a marked dependence
of reference values on sex (5); in adults from 20 to 50
years old this may be explained by an interrelationship
between bone alkaline phosphatase values and sex hor-
mones, especially oestrogens (8).
Our results for bone alkaline phosphatase activity con-
centration (äs determined by precipitation with wheat-
germ lectin) in patients with hepatobiliary diseases are
concordant with those reported by Behr & Barnert (9),
who observed that in more than half of patients with
hepatitis of differing origin, äs well äs in patients with
cholestasis, bone alkaline phosphatase activity concen-
tration (äs assessed by precipitation with wheat-germ
lectin) was increased (up to 725 U/l) without ac-
companying signs of bone affection. In coiitrast to the
liver alkaline phosphatase molecules that occur in
serum, those isolated from liver tissue can be precipi-
tated with wheat-germ lectin, presumably because mem-
brane-localized glycosyltransferases modify the enzyme
molecules äs they pass into the intravasal space (9). As
a result of increased liver cell permeability in patients
with hepatobiliary diseases, liver alkaline phosphatase is
possibly not modified by the membrane-localized glyco-
syltransferases mentioned above and is therefore pre-
cipitated by wheat-germ lectin, resulting in falsely high
values for bone alkaline phosphatase activity concen-
tration. Biliary alkaline phosphatase, which is a complex
of liver alkaline phosphatase with membrane fragments,
is not responsible for implausibly high values of bone
alkaline phosphatase activity concentration, because Tri-
ton X-100 prevents coprecipitation of this isoform (9).
Falsely high levels of bone alkaline phosphatase mass
concentration are possibly due to cross-reactivity of the
antibodies employed for the immunoassay of bone alka-
line phosphatase with liver alkaline phosphatase (10), so
that the diagnostic validity of the test is strongly limited
in patients with an increased release of liver alkaline
phosphatase into plasma.
Further investigations are required to determine the
clinical value of the immunochemical determination of
bone alkaline phosphatase mass concentration in serum.
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